Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial

BACKGROUND: In the CheckMate-141 trial, nivolumab conferred a survival benefit in patients with recurrent or metastatic refractory squamous cell carcinoma (SCC) head and neck cancer (HNC). Here, we examined the efficacy of nivolumab in patients with histological subtypes or primary sites of HNC not...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer Manag Res
Main Authors: Sato, Yasuyoshi, Fukuda, Naoki, Wang, Xiaofei, Urasaki, Tetsuya, Ohmoto, Akihiro, Nakano, Kenji, Yunokawa, Mayu, Ono, Makiko, Sato, Yukiko, Mitani, Hiroki, Tomomatsu, Junichi, Takahashi, Shunji
Format: Artigo
Sprog:Inglês
Udgivet: Dove 2020
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7280058/
https://ncbi.nlm.nih.gov/pubmed/32581587
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S249393
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker